Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Adv Drug Deliv Rev. 2012 Nov 23;65(8):1012–1019. doi: 10.1016/j.addr.2012.11.001

Figure 2.

Figure 2

Cartoon of some strategies used to target therapeutic agents to the TFR on cancer cells. This figure has been adapted with permission from and thanks to Daniels et al. [14] and provides an overview of some of the approaches that have been taken. As shown, strategies include attachment of cargos directly to TF, or to peptides that bind to the TFR, in addition to monoclonal antibodies or single chain antibody fragments (designated scFv) specific for the extracellular domain of the TFR. The therapeutic agents are delivered either as direct conjugates or enclosed in carriers. Therapeutic payloads include chemotherapeutic peptides, small drugs, proteins, radionuclides, genes in vectors, and oligonucleotides. The TFR is shown as a homodimer; importantly each monomer of the TFR is capable of binding a molecule of TF (although for clarity only the binding of a single TF is shown). Likewise for simplicity in the antibody and related scFv targeting sections a single TFR homodimer is shown in the cartoon.